Fennec Pharmaceuticals (TSE:FRX) Stock Passes Above 50 Day Moving Average – Should You Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$7.55 and traded as high as C$8.87. Fennec Pharmaceuticals shares last traded at C$8.87, with a volume of 121 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Stephens upgraded shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Trading Down 2.6 %

The stock has a market cap of C$241.59 million, a P/E ratio of 88.30 and a beta of 0.25. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17. The firm’s fifty day moving average price is C$7.61 and its two-hundred day moving average price is C$7.65.

Insider Activity

In other news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of the company’s stock in a transaction on Monday, November 18th. The stock was acquired at an average price of C$3.43 per share, with a total value of C$54,248.88. Also, Director Rostislav Christov Raykov acquired 25,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was purchased at an average price of C$3.87 per share, for a total transaction of C$96,840.00. In the last quarter, insiders have purchased 41,612 shares of company stock worth $157,868. 16.20% of the stock is currently owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.